Home Featured Page 135

Featured

Latest

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

Historical Insights on the Psychedelic Renaissance

PT386 – Vital Psychedelic Conversations

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™...

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Ehave Provides Progress Update on its HPPD Study with University of...

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

Historical Insights on the Psychedelic Renaissance

PT386 – Vital Psychedelic Conversations

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday,...

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding...

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™...

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Ehave Provides Progress Update on its HPPD Study with University of...

The Agenda for Economic Analyses of Psychedelic-assisted Therapy

A Perspective on Providers: Scaling PAT in a Time of Therapist...

EDITOR PICKS

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

Psychedelic Philanthropy Is Entering Its Next Phase

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY